Chlorphenesin Carbamate

Summary

Chlorphenesin Carbamate (CHEMBL607710) is an approved small-molecule muscle relaxant (ATC D01AE07); indicated across 1 condition including exocrine pancreatic carcinoma.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: D01AE07
• Indications: 1 condition
• Clinical trials: 1
• Chemistry: 245.66 Da · C10H12ClNO4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL607710
Name	Chlorphenesin Carbamate
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	2724
ChEBI	CHEBI:3643
ATC	D01AE07
Molecular formula	C10H12ClNO4
Molecular weight	245.66
InChIKey	SKPLBLUECSEIFO-UHFFFAOYSA-N

SMILES: C1=CC(=CC=C1OCC(COC(=O)N)O)Cl

IUPAC name: [3-(4-chlorophenoxy)-2-hydroxypropyl] carbamate

ChEBI definition: The carbamate ester of the primary hydroxy group of chlorphenesin. A centrally acting skeletal muscle relaxant, it is used in the symptomatic treatment of painful muscle spasm.

Pharmacological roles (ChEBI): muscle relaxant.

Also known as: Chlorphenesin, Chlorphenesin carbamate, Chlorphenesine, Clorfenesina, Maolate, NSC-6401, NSC-82943, U-19,646, U-19646, chlorphenesin, CHLORPHENESIN CARBAMATE, SID56463366

Patent coverage: 472 distinct patent families (1,392 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
exocrine pancreatic carcinoma	1	MONDO:0005192	EFO:0002618

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05083780	PHASE1	ACTIVE_NOT_RECRUITING	Hydroxychloroquine and Chlorphenesin Carbamate in Combination With mFOLFIRINOX in Pancreatic Cancer

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).